On February 26, 2024, RS Fund LP announced that NeuroMetrix, Inc. publicized a strategic review which led to the purchase by RS Fund LP and there might be an intention to influence. RS Fund stated that there is a potential for an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries. RS Fund also added that there is also a potential for any material change in the present capitalization or dividend policy of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.44 USD | +0.68% | +2.54% | +23.33% |
Apr. 19 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
Apr. 19 | Sector Update: Health Care Stocks Rise Friday Afternoon | MT |
1st Jan change | Capi. | |
---|---|---|
+23.33% | 8.82M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- NURO Stock
- News NeuroMetrix, Inc.
- RS Fund Discloses its Views on NeuroMetrix